eXoZymes (EXOZ) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pelthos Therapeutics (PTHS) has outperformed eXoZymes (EXOZ) over the past year, losing 74.9% versus a loss of 81.8%. eXoZymes is the larger company by market cap ($27.4 million vs $25.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXOZ | PTHS |
|---|---|---|
| Share price | $2.91 | $6.38 |
| Market cap | $27.42M | $25.08M |
| 1-day change | -14.05% | -8.73% |
| YTD return | -73.35% | -79.42% |
| 1-year return | -81.84% | -74.88% |
| EPS (TTM) | $-1.16 | $-23.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.80M |
| Net income (latest FY) | $-9.16M | $-43.32M |
| Gross margin | — | 76.25% |
| Operating margin | — | -193.09% |
| Net margin | — | -257.93% |
| 52-week high | $16.16 | $31.62 |
| 52-week low | $2.81 | $6.02 |
| Distance from 52-week high | -82.02% | -79.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | — | +732.92% |
| Average volume | 10.14K | 54.38K |
| Shares outstanding | 9.44M | 3.93M |
| Employees | 32 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About eXoZymes
EXOZ stock →eXoZymes, Inc. operates as a development stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
EXOZ vs PTHS FAQ
Which is bigger, eXoZymes or Pelthos Therapeutics?
eXoZymes (EXOZ) is larger, with a market capitalization of $27.42M compared with $25.08M for Pelthos Therapeutics (PTHS).
Which stock has performed better over the past year, EXOZ or PTHS?
PTHS returned -74.88% over the past 12 months, compared with -81.84% for EXOZ (price return, excluding dividends). Past performance does not predict future results.
Are eXoZymes and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.